You are here
- Home
- Diseases & Conditions
- All Diseases and Conditions
A Phase II, Open label, Non randomised, Non comparative, Multicentre study to assess the efficacy and safety of olaparib given orally twice daily in patients with advanced cancers who have a confirmed genetic BRCA 1 and/or BRCA2 mutation
- Disease
- cancer
- Drug Name
- Olaparib
- Generic Name
- Olaparib (AZD2281)
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- II
- Start Date
- Feb 21, 2010
- Study Name
- D0810C00042
- Study Id
- D0810C00042
- ClinicalTrials.gov ID
- NCT01078662
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
